Fragment Screening of MIF by Surface Plasmon Resonance.

Emmanuel K Yeboah, Natalie A Borg, Stephen J Headey

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Emmanuel K YeboahImmunity and Immune Evasion Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, 3083, Australia.

Natalie A BorgImmunity and Immune Evasion Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, 3083, Australia.

Stephen J HeadeySchool of Science, RMIT University, 124 La Trobe St, Melbourne, VIC, 3000, Australia. stephen.headey@rmit.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cytokine MIF is implicated in several autoimmune and inflammatory conditions and is elevated in several types of cancer, making it a promising therapeutic target. Small-molecule MIF inhibitors provide tools to elucidate MIFs' immune regulatory roles, and their further optimization could lead to potential therapeutics. Surface plasmon resonance (SPR) is a relatively high-throughput and sensitive biophysical technique used in drug discovery for screening small organic compounds (termed fragments) for their interactions with macromolecules. SPR analysis can provide the association and dissociation rate constants and the equilibrium binding constant for protein interactions. As such, SPR also provides a valuable orthogonal technique to determine compound binding (K

Indexed as

Drug DiscoveryIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsSurface Plasmon ResonanceHumansProtein BindingSmall Molecule LibrariesIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, humanSmall Molecule LibrariesFragment-based drug discoveryInhibitorsMIFSurface plasmon resonance

Identifiers

PMID42129111

DOI10.3390/s22082901

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.